作者
Anthony V Moorman, Christine J Harrison, Georgina AN Buck, Sue M Richards, Lorna M Secker-Walker, Mary Martineau, Gail H Vance, Athena M Cherry, Rodney R Higgins, Adele K Fielding, Letizia Foroni, Elisabeth Paietta, Martin S Tallman, Mark R Litzow, Peter H Wiernik, Jacob M Rowe, Anthony H Goldstone, Gordon W Dewald, Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group
发表日期
2007/4/15
期刊
Blood
卷号
109
期号
8
页码范围
3189-3197
出版商
American Society of Hematology
简介
Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented. Patients with a Ph chromosome, t(4;11)(q21;q23), t(8;14)(q24.1;q32), complex karyotype (5 or more chromosomal abnormalities), or low hypodiploidy/near triploidy (Ho-Tr) all had inferior rates of event-free and overall survival when compared with other patients. In contrast, patients with high hyperdiploidy or a del(9p) had a …
引用总数
学术搜索中的文章
AV Moorman, CJ Harrison, GAN Buck, SM Richards… - Blood, 2007